Pegcetacoplan Bests Eculizumab for PNH Patients
Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with
family / friend
Oral Azacitidine Improves, Sustains Health-Related QoL in AML
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with
Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine
Crovalimab
An experimental complement inhibitor C5 monoclonal antibody.
Treatment Approaches in AML: Key Testing for Personalized Care
VIDEO
Description:
Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo.
Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML
Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.
Chetasi Talati, MD
Chetasi Talati, MD
ASH Issues Guidelines on Newly Diagnosed AML in Older Adults
MDS Treatment, Inqovi: Dr. Amer Zeidan Explains the Use of this Treament
The recently-approved hypomethylating treatment, Inoqvi, is a daily oral version of two IV or subcutaneous medications. Listen to Dr. Amer Zeidan of Yale Cancer Center explain which MDS patients could qualify, and what it means for their treatment at the link.